WO1998003171A3 - Use of inhibitors of cyp2a6 for regulating nicotine metabolism - Google Patents

Use of inhibitors of cyp2a6 for regulating nicotine metabolism Download PDF

Info

Publication number
WO1998003171A3
WO1998003171A3 PCT/CA1997/000506 CA9700506W WO9803171A3 WO 1998003171 A3 WO1998003171 A3 WO 1998003171A3 CA 9700506 W CA9700506 W CA 9700506W WO 9803171 A3 WO9803171 A3 WO 9803171A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyp2a6
inhibitors
nicotine metabolism
regulating nicotine
regulating
Prior art date
Application number
PCT/CA1997/000506
Other languages
French (fr)
Other versions
WO1998003171A2 (en
Inventor
Edward M Sellers
Rachel F Tyndale
Original Assignee
Edward M Sellers
Rachel F Tyndale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edward M Sellers, Rachel F Tyndale filed Critical Edward M Sellers
Priority to EP97930283A priority Critical patent/EP0954304A2/en
Priority to AU34320/97A priority patent/AU742628B2/en
Priority to BR9710728-0A priority patent/BR9710728A/en
Priority to CA002227423A priority patent/CA2227423A1/en
Priority to JP10506399A priority patent/JP2000515516A/en
Priority to NZ334205A priority patent/NZ334205A/en
Publication of WO1998003171A2 publication Critical patent/WO1998003171A2/en
Publication of WO1998003171A3 publication Critical patent/WO1998003171A3/en
Priority to PCT/CA1998/001093 priority patent/WO1999027919A2/en
Priority to US12/237,713 priority patent/US20090285797A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A method of regulating nicotine metabolism in an individual comprising selectively inhibiting CYP2A6.
PCT/CA1997/000506 1996-07-17 1997-07-17 Use of inhibitors of cyp2a6 for regulating nicotine metabolism WO1998003171A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP97930283A EP0954304A2 (en) 1996-07-17 1997-07-17 Methods for regulating nicotine metabolism
AU34320/97A AU742628B2 (en) 1996-07-17 1997-07-17 Methods for regulating nicotine metabolism
BR9710728-0A BR9710728A (en) 1996-07-17 1997-07-17 Processes for regulation of nicotine metabolism
CA002227423A CA2227423A1 (en) 1996-07-17 1997-07-17 Methods for regulating nicotine metabolism
JP10506399A JP2000515516A (en) 1996-07-17 1997-07-17 How to regulate nicotine metabolism
NZ334205A NZ334205A (en) 1996-07-17 1997-07-17 Method for regulating nicotine metabolism through inhibition of CYP2A6 and CYP2B6 liver enzymes
PCT/CA1998/001093 WO1999027919A2 (en) 1997-07-17 1998-12-01 Cyp2a enzymes and their use in therapeutic and diagnostic methods
US12/237,713 US20090285797A1 (en) 1996-07-17 2008-09-25 Use of inhibitors of cyp2a6 for regulating nicotine metabolism

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2194096P 1996-07-17 1996-07-17
US60/021,940 1996-07-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/715,548 Division US20050032844A1 (en) 1996-07-17 2003-11-19 Methods for regulating nicotine metabolism

Publications (2)

Publication Number Publication Date
WO1998003171A2 WO1998003171A2 (en) 1998-01-29
WO1998003171A3 true WO1998003171A3 (en) 1998-02-26

Family

ID=21806974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1997/000506 WO1998003171A2 (en) 1996-07-17 1997-07-17 Use of inhibitors of cyp2a6 for regulating nicotine metabolism

Country Status (8)

Country Link
EP (1) EP0954304A2 (en)
JP (1) JP2000515516A (en)
CN (1) CN100502860C (en)
AU (1) AU742628B2 (en)
BR (1) BR9710728A (en)
CA (1) CA2227423A1 (en)
NZ (1) NZ334205A (en)
WO (1) WO1998003171A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312851A1 (en) † 1997-12-01 1999-06-10 Nicogen, Inc. Therapeutic and diagnostic methods dependent on cyp2a enzymes
US6492115B1 (en) 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
US20080188527A1 (en) * 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
CN106046015B (en) * 2016-06-08 2018-06-05 北京大学 The Specific probe of a kind of Cytochrome P450 2A6 enzymes and its application
CN112391397B (en) * 2020-11-25 2023-01-31 云南中烟工业有限责任公司 Tobacco flavone monooxygenase gene NtCYP75B2 and application thereof
CN114646718A (en) * 2022-04-07 2022-06-21 国家烟草质量监督检验中心 Method for evaluating nicotine metabolism dynamics absorbed by oral route and digestive tract route when people use buccal tobacco products

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034679A2 (en) * 1994-06-16 1995-12-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Defects in drug metabolism

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034679A2 (en) * 1994-06-16 1995-12-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Defects in drug metabolism

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A. TSUJIMOTO ET AL.: "A study of the nature of pilocarpine inhibition of hepatic drug-metabolizing enzymes.", BIOCHEM. PHARMACOL., vol. 26, no. 21, 1977, pages 2072 - 2074, XP002050004 *
A. TSUJIMOTO ET AL.: "Potent inhibitory action of pilocarpine on hepatic drug metabolism.", JPN. J. PHARMACOL., vol. 22, no. 5, 1972, pages 736 - 739, XP002050003 *
G.A. KYEREMATEN ET AL.: "Metabolism of nicotine by hepatocytes.", BIOCHEM. PHARMACOL., vol. 40, no. 8, 1990, pages 1747 - 1756, XP002050006 *
H. FOTH ET AL.: "Nicotine metabolism in isolated perfused lung and liver of phenobarbital- and benzoflavone-treated rats.", ARCH. TOXICOL., vol. 65, no. 1, 1991, pages 68 - 72, XP002050005 *
H. YAMAZAKI ET AL.: "Cytochrome P450 sE1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes.", CARCINOGENESIS, vol. 13, no. 10, 1992, pages 1789 - 1794, XP002050007 *
M. NAKAJIMA ET AL.: "Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.", J. PHARMACOL. EXP. THERAP., vol. 277, no. 2, 1996, pages 1010 - 1015, XP002050001 *
M. NAKAJIMA ET AL.: "Role of human cytochrome P4502A6 in C-oxidation of nicotine.", DRUG METABOL. DISPOS., vol. 24, no. 11, 1996, pages 1212 - 1217, XP002050002 *

Also Published As

Publication number Publication date
BR9710728A (en) 2000-10-31
CA2227423A1 (en) 1998-01-29
CN100502860C (en) 2009-06-24
AU742628B2 (en) 2002-01-10
WO1998003171A2 (en) 1998-01-29
JP2000515516A (en) 2000-11-21
NZ334205A (en) 2001-04-27
EP0954304A2 (en) 1999-11-10
CN1230112A (en) 1999-09-29
AU3432097A (en) 1998-02-10

Similar Documents

Publication Publication Date Title
AU5823198A (en) Method and apparatus for playing poker
AU3909395A (en) System and method for delivering multiple stents
AU1313400A (en) A method and system for providing a web-sharable personal database
AU6016098A (en) Method and apparatus for attribute selection
AU8256698A (en) System and method for dynamic selection of appropriate postal rates based on metering data
HUP0101809A3 (en) Inhibitors of type 5 and type 3 17betha-hydroxysteroid dehydrogenase and methods for their use
AU1384400A (en) Record carrier, and apparatus and method for playing back a record carrier, and method of manufacturing a record carrier
AU6185096A (en) Bingo game management method
AU6250299A (en) Method for reducing nicotine dependency
EP0583074A3 (en) Angiotensin converting enzyme inhibitor and method for preparing same.
EP0796566A3 (en) Apparatus for pitting prunes or dates
AU5835896A (en) Method and apparatus for planting runners
ZA9610696B (en) Method for placing indicia on substrates having an enamel band thereon.
AU1705400A (en) Method and composition for treating and preventing tuberculosis
AU3768095A (en) Herbicidal composition and method
AU6924898A (en) Method and device for keeping watch over premises
AU5558696A (en) Article and method for dilating respiratory passages
AU6733396A (en) Method and device for distributing letters
GB9425701D0 (en) Enzyme inhibitors
AU3830895A (en) Dimeric il-4 inhibitors
WO1998003171A3 (en) Use of inhibitors of cyp2a6 for regulating nicotine metabolism
AU2157999A (en) Method for pickling and passivating special steel
AU1605997A (en) Steel-making method and plant
AU2931695A (en) Method for forming soles and device therefor
AU4567999A (en) Distributed amplifier and method therefor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97197913.8

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2227423

Country of ref document: CA

Ref document number: 2227423

Country of ref document: CA

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/000755

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1997930283

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 334205

Country of ref document: NZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09214851

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997930283

Country of ref document: EP